Evaluation of new tumors in the setting of stage I/IIA mycosis fungoides

Cynthia R. Harrington, David R. Guillén, Amit G. Pandya

Research output: Contribution to journalArticle

Abstract

Although mycosis fungoides is usually a slowly progressive indolent lymphoma, new cutaneous tumors might signal an aggressive phase of the disease. In order to provide appropriate therapeutic management when such tumors arise, it is important to make a correct diagnosis, which requires a bridge between clinical and histopathologic evaluations of the tumors. In this article, we describe 4 patients with preexisting diagnoses of mycosis fungoides, each of whom developed a distinct, new skin tumor. These tumors represented the following: mycosis fungoides without transformation, large-cell transformation of mycosis fungoides, lymphomatoid papulosis-associated CD30+ lymphoproliferative disorder arising in a patient with mycosis fungoides, and a primary cutaneous CD30+ lymphoproliferative disorder arising in a patient with mycosis fungoides. Each new and histologically distinct tumor was identified and treated according to a diagnosis concluded by careful clinicopathologic correlation, allowing for the selection of appropriate treatment in each case.

Original languageEnglish (US)
Pages (from-to)480-485
Number of pages6
JournalClinical Lymphoma and Myeloma
Volume7
Issue number7
DOIs
StatePublished - Jul 2007

Keywords

  • Bexarotene
  • Cutaneous T-cell lymphoma
  • Methotrexate
  • Skin toxicity
  • Topical nitrogen mustard

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluation of new tumors in the setting of stage I/IIA mycosis fungoides'. Together they form a unique fingerprint.

  • Cite this